• Nutriband entered an amended three-year USD 5 million credit line facility on June 1, 2026, replacing a prior USD 5 million facility set to expire July 13, 2026.
• Drawdowns carry 7% annual interest.
• Facility bars the lender from converting outstanding amounts into common stock.
• Financing targets funding through FDA approval into commercial-scale manufacturing for AVERSA Fentanyl.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nutriband Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-070378), on June 22, 2026, and is solely responsible for the information contained therein.